SAVVY (C31G) gel for prevention of HIV infection in women: a Phase 3, double-blind, randomized, placebo-controlled trial in Ghana. - Wikidata - awgldk - TriplyDB

SAVVY (C31G) gel for prevention of HIV infection in women: a Phase 3, double-blind, randomized, placebo-controlled trial in Ghana.

SAVVY (C31G) gel for prevention of HIV infection in women: a Phase 3, double-blind, randomized, placebo-controlled trial in Ghana.

http://www.wikidata.org/entity/Q33311277

about

SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria Long-term consistent use of a vaginal microbicide gel among HIV-1 sero-discordant couples in a phase III clinical trial (MDP 301) in rural south-west Uganda Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples Topical microbicides for prevention of sexually transmitted infections Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples Blocking HIV-1 transmission in the female reproductive tract: from microbicide development to exploring local antiviral responses Advances in HIV microbicide development Microbicides and their potential as a catalyst for multipurpose sexual and reproductive health technologies Adherence in the CAPRISA 004 tenofovir gel microbicide trial Stampidine as a promising antiretroviral drug candidate for pre-exposure prophylaxis against sexually transmitted HIV/AIDS In vitro surfactant structure-toxicity relationships: implications for surfactant use in sexually transmitted infection prophylaxis and contraception Rectal transmission of transmitted/founder HIV-1 is efficiently prevented by topical 1% tenofovir in BLT humanized mice Expression of Genes for Drug Transporters in the Human Female Genital Tract and Modulatory Effect of Antiretroviral Drugs Abasic phosphorothioate oligomers inhibit HIV-1 reverse transcription and block virus transmission across polarized ectocervical organ cultures.HIV-prevention science at a crossroads: advances in reducing sexual risk.Formulation, pharmacokinetics and pharmacodynamics of topical microbicides.Overview of microbicides for the prevention of human immunodeficiency virus.The importance of the vaginal delivery route for antiretrovirals in HIV prevention.Efficacy dilution in randomized placebo-controlled vaginal microbicide trials Semi-solid gels function as physical barriers to human immunodeficiency virus transport in vitro.Surfactants as microbicides and contraceptive agents: a systematic in vitro study.Interim data monitoring to enroll higher-risk participants in HIV prevention trials Targeting Trojan Horse leukocytes for HIV prevention.Advances in the Development of Microbicides for the Prevention of HIV Infection.State of the science of adherence in pre-exposure prophylaxis and microbicide trials.Historical development of vaginal microbicides to prevent sexual transmission of HIV in women: from past failures to future hopes.Methodologies for evaluating HIV prevention intervention (populations and epidemiologic settings)Contraception and pregnancy in microbicide trials.Youth-specific considerations in the development of preexposure prophylaxis, microbicide, and vaccine research trials.Modelling sexual transmission of HIV: testing the assumptions, validating the predictions.Bridging the gap between preclinical and clinical microbicide trials: blind evaluation of candidate gels in murine models of efficacy and safety.Topical microbicides and HIV prevention in the female genital tract Pregnancy incidence and correlates during the HVTN 503 Phambili HIV vaccine trial conducted among South African women.The meaning of adherence when behavioral risk patterns vary: obscured use- and method-effectiveness in HIV-prevention trials.Decreased cervical epithelial sensitivity to nonoxynol-9 (N-9) after four daily applications in a murine model of topical vaginal microbicide safety Vaginal microbicides for reducing the risk of sexual acquisition of HIV infection in women: systematic review and meta-analysis.Preventing mucosal HIV transmission with topical microbicides: challenges and opportunities.Female genital tract secretions and semen impact the development of microbicides for the prevention of HIV and other sexually transmitted infections.Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial

P2860

Q21144355-B0D7AD12-E40D-452C-9A96-77AB14B792C0 Q21203732-BCC7C51E-9E4E-4E6D-9042-E2595FFD01A9 Q24197939-D570049C-157A-4527-A136-BE5DE96004CD Q24202832-19977151-F886-4539-B3F8-95ADE74EBEE0 Q24234597-25EA2BE4-3B91-47C3-8143-1EAD4246CADB Q24234903-7A417D1D-2C61-4116-B817-2EC6B2A54EDF Q26774878-4EA4079E-A037-4D43-B4D6-5E4A01F236A9 Q26852858-23B9F310-A48B-4B2D-BB26-45377E745866 Q27026257-FC8538E1-92D0-42EE-84B8-F9E4810A0CBA Q28236148-AD34C335-DAF2-46E2-8D84-935C6AD289E1 Q28260539-F5885521-2B6B-4896-96F1-955F0323E1FC Q28478153-3F28A70D-5A14-43D7-9622-F775BECC9C54 Q28488527-04ADBFAF-E4BD-4D00-BCE3-A769341BA5BC Q28548592-4A9B13DD-BD23-4F57-8729-066E1AA60C89 Q30366821-0CFA19EC-FD78-4ACF-BAAD-C468359FDA4F Q30378142-39E4BD1A-6527-46A4-B040-070111A6738F Q30412592-9E07A140-4321-48D5-8A28-628646F5E7D0 Q30413777-9565392C-2D2F-47B7-BA3F-FC2713AC79FE Q30414890-B71C65D7-0683-4E32-8528-5DA068C949E8 Q30491264-3C4EE11A-ACD0-4A06-91AE-3EFA23375E0A Q30499386-EC5B04C7-CD34-4CDC-8DA4-C93AB28A55B0 Q33358081-65D64319-71D6-4599-AD40-E80A48F55F43 Q33473028-9169B3C8-6A63-4B19-9C31-1665810B6490 Q33518390-6996A8BD-863F-4EFE-8DF2-2D18B38BA7F2 Q33762924-E8BB561E-82F5-4753-8772-2C400FFBB44D Q33798685-2FF29DA6-1C12-49E3-BDBC-09275C385DBB Q33821090-9710442B-076C-4F46-A034-521404202FC5 Q33904091-0BAD32D0-AA44-47E9-833C-2E6D10F7ABD2 Q33924850-DC2EFB28-6D08-40CE-9A20-D2D454D3C233 Q34030735-2C7C1EB7-7217-446C-B298-5C7A7FB97ADB Q34071168-87E00A6B-4F22-4145-B81B-0C362550A910 Q34078011-958864FD-DAE4-4FF7-855E-70C5DA2EB76C Q34086820-C4E2E1BC-8CED-4D32-A4D5-3211E9A448CB Q34244965-3BB548C3-99E4-4086-87EB-6F50FE165598 Q34411982-B94D3F19-D9B7-448B-85B2-7AF7A643359C Q34425552-DEA3D1FB-3C9B-4BB7-81FA-3AF356D5C99C Q34468210-A2572B11-563D-41FD-B033-E423D8BB1289 Q34548621-EDB72274-FFFF-4F04-A336-5B0EB4E95BD7 Q34680240-1D23BB63-CD4B-4A0A-96AB-D62B3EA970C5 Q34712820-D124433C-7D49-409B-BDC9-4E9B245A6F49

P2860

SAVVY (C31G) gel for prevention of HIV infection in women: a Phase 3, double-blind, randomized, placebo-controlled trial in Ghana.

http://www.wikidata.org/entity/Q33311277

description

2007 nî lūn-bûn

@nan

2007 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

SAVVY (C31G) gel for preventio ...... ebo-controlled trial in Ghana.

@ast

SAVVY (C31G) gel for preventio ...... ebo-controlled trial in Ghana.

@en

SAVVY (C31G) gel for preventio ...... ebo-controlled trial in Ghana.

@nl

type

label

SAVVY (C31G) gel for preventio ...... ebo-controlled trial in Ghana.

@ast

SAVVY (C31G) gel for preventio ...... ebo-controlled trial in Ghana.

@en

SAVVY (C31G) gel for preventio ...... ebo-controlled trial in Ghana.

@nl

prefLabel

SAVVY (C31G) gel for preventio ...... ebo-controlled trial in Ghana.

@ast

SAVVY (C31G) gel for preventio ...... ebo-controlled trial in Ghana.

@en

SAVVY (C31G) gel for preventio ...... ebo-controlled trial in Ghana.

@nl

P1433

Q33311277-96149A01-8833-4734-88F6-3E7E73991A29

P1476

Q33311277-6DD4D5C2-20E1-4C9A-A558-5444EF533D90

P2093

Q33311277-1390538D-ED3C-4C04-B3A4-26113F03F774

Q33311277-31CFBC48-0C0D-46AF-AB23-D80F5132C9B6

Q33311277-3278F4D8-D3D5-40F8-82E6-5F30D2EC3F1C

Q33311277-47C77850-FBB9-4033-9B33-A196E59DA49E

Q33311277-566EAC1C-78B6-4E9F-8B69-80F907C7C5DF

Q33311277-7B200469-C325-4816-8F82-8593FDC3ACD4

Q33311277-9A12944B-1F4A-4979-BFA7-67F773F9B262

Q33311277-AD438A91-AEC6-418C-86B2-D6CF8DD37FED

Q33311277-B9C48361-6DBB-4193-915B-C3C9B16BD46A

Q33311277-D1671637-4169-4F09-9576-910471ABB034

P2860

Q33311277-1742A8B4-ED3B-4DA0-856F-FBB7EB30AC54

Q33311277-2753EC90-06A4-41BE-9056-6F75232571C6

Q33311277-355FC49A-A3F3-4A4A-8225-CC0B31D697DA

Q33311277-3E934CDC-4FB0-47BE-A48E-50D418491B80

Q33311277-477406CF-0DAE-495C-8F43-3519A28C799A

Q33311277-4EFE2018-3A3E-4D0C-88B5-91DC2E1AEE67

Q33311277-50459CE2-FC42-4950-8283-5240E5D9EFD2

Q33311277-54137F39-BE0E-4C1D-860D-4D7A0F86382F

Q33311277-60550D88-1F77-4A16-8516-6E5EB3A70A93

Q33311277-D3A70DF0-4226-4B97-897E-ED39A681EC1D

P304

Q33311277-8DF92633-2341-469B-A133-DCAEB6DBA037

P31

Q33311277-AAE6A1A9-5551-410F-9054-F00189E9F0AA

P356

Q33311277-9E66082D-6C85-4395-BAF9-1D050D374257

P407

Q33311277-CCD698C2-067A-4DC1-9C49-63F5E3F3364F

P433

Q33311277-2CFBE9D6-45D8-4049-965F-7FEF72173354

P478

Q33311277-D6FE12CC-09BE-4BFA-9D50-27D3AB0D9A9F

P50

Q33311277-B9721C9C-345F-4C00-9493-466678AA478F

P577

Q33311277-6D5FA546-FD78-4370-807D-94C5870BC671

P5875

Q33311277-0369D8D6-7133-4745-B460-81B23AF4D4F7

P698

Q33311277-65241EA5-D480-4B8A-B768-8F4CF16DC7AB

P921

Q33311277-17D5A8D3-3669-458C-8EA7-6BD74D12DE1B

Q33311277-1CDDD048-75C9-4CBA-B46F-04B51B81CCDE

Q33311277-8DF93966-97BF-4D17-9E2A-F08C5FDC1E1A

Q33311277-D7450044-8143-4835-B7E0-5D06F4D6306C

P932

Q33311277-CA0F3F8C-59C8-4C8A-BF13-3A48D788BC1C

P356

JOURNAL.PONE.0001312

P1433

P1476

SAVVY (C31G) gel for preventio ...... ebo-controlled trial in Ghana.

@en

P2093

Amanda Troxler

http://www.w3.org/2001/XMLSchema#string

Andrew Yiadom Boakye

http://www.w3.org/2001/XMLSchema#string

Baafuor Kofi Opoku

http://www.w3.org/2001/XMLSchema#string

Laneta Dorflinger

http://www.w3.org/2001/XMLSchema#string

Leigh Peterson

http://www.w3.org/2001/XMLSchema#string

Margaret Owusu-Amoako

http://www.w3.org/2001/XMLSchema#string

Ronald Roddy

http://www.w3.org/2001/XMLSchema#string

Rosalie Dominik

http://www.w3.org/2001/XMLSchema#string

Wes Rountree

http://www.w3.org/2001/XMLSchema#string

William Kwabena Ampofo

http://www.w3.org/2001/XMLSchema#string

P2860

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials

Sodium dodecyl sulfate and C31G as microbicidal alternatives to nonoxynol 9: comparative sensitivity of primary human vaginal keratinocytes.

Microbicide drug candidates to prevent HIV infection.

Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial.

Male tolerance study of 1% C31G.

Microbicides--evaluating multiple formulations of C31G.

A phase I comparative postcoital testing study of three concentrations of C31G.

A randomized Phase I vaginal safety study of three concentrations of C31G vs. Extra Strength Gynol II.

Will microbicide trials yield unbiased estimates of microbicide efficacy?

The effects of frequent nonoxynol-9 use on the vaginal and cervical mucosa.

P304

e1312

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0001312

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

P577

2007-12-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5757017

http://www.w3.org/2001/XMLSchema#string

P698

18091987

http://www.w3.org/2001/XMLSchema#string

P921

phase III clinical trial

prevention of HIV/AIDS

P932

2129116

http://www.w3.org/2001/XMLSchema#string